Gradalis

Dallas, Texas, United States · Biotechnology, Health Care, Therapeutics · 25 employees

Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types.

See plans & pricing → Track Gradalis’s funding, hiring, and signals — with verified contacts — on Fundz.